Veradermics (MANE) Other Accumulated Expenses (2025 - 2026)

Veradermics (MANE) posted Other Accumulated Expenses of $39000.0 for Q1 2026, down 17.02% on a QoQ basis from $47000.0 in Q4 2025.

Veradermics (MANE) Other Accumulated Expenses (2025 - 2026) Analysis & Trends

Veradermics' Other Accumulated Expenses history runs 2 years deep, the most recent figure standing at $39000.0 for Q1 2026.

Quarterly Other Accumulated Expenses changed N/A year-over-year to $39000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39000.0 (changed N/A YoY) and the FY2025 annual result came in at $47000.0, changed N/A from the prior year.
Other Accumulated Expenses was $39000.0 for Q1 2026 at Veradermics, down from $47000.0 in the prior quarter.
Across five years, Other Accumulated Expenses topped out at $47000.0 in Q4 2025 and bottomed at $39000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Veradermics	2.63 Bn	2.63 Bn	-

Download Data

Date	Value
Mar 31, 2026	39,000.00
Dec 31, 2025	47,000.00